Aclaris Therapeutics, Inc. (ACRS) Given a $50.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in a report published on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on ACRS. ValuEngine cut shares of Aclaris Therapeutics from a hold rating to a sell rating in a research report on Tuesday, June 6th. Jefferies Group LLC reiterated a buy rating and set a $36.00 price objective on shares of Aclaris Therapeutics in a research report on Wednesday, June 28th. Guggenheim reiterated a buy rating and set a $40.00 price objective on shares of Aclaris Therapeutics in a research report on Tuesday, July 4th. BidaskClub upgraded shares of Aclaris Therapeutics from a hold rating to a buy rating in a research report on Monday, July 24th. Finally, JMP Securities reiterated an outperform rating and set a $39.00 price objective on shares of Aclaris Therapeutics in a research report on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Aclaris Therapeutics currently has a consensus rating of Buy and a consensus target price of $41.25.

Aclaris Therapeutics (NASDAQ ACRS) opened at 27.61 on Wednesday. The stock’s 50 day moving average is $25.92 and its 200-day moving average is $27.19. Aclaris Therapeutics has a 12 month low of $20.15 and a 12 month high of $33.25. The company’s market capitalization is $738.18 million.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. On average, analysts expect that Aclaris Therapeutics will post ($3.10) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics, Inc. (ACRS) Given a $50.00 Price Target at Cantor Fitzgerald” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://transcriptdaily.com/2017/10/08/aclaris-therapeutics-inc-acrs-given-a-50-00-price-target-at-cantor-fitzgerald.html.

In other news, Director Andrew N. Schiff acquired 108,601 shares of the firm’s stock in a transaction dated Wednesday, August 16th. The stock was bought at an average cost of $23.02 per share, for a total transaction of $2,499,995.02. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 16.30% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Ardsley Advisory Partners acquired a new stake in shares of Aclaris Therapeutics during the second quarter worth $407,000. California State Teachers Retirement System increased its position in shares of Aclaris Therapeutics by 60.8% during the second quarter. California State Teachers Retirement System now owns 35,696 shares of the biotechnology company’s stock worth $968,000 after buying an additional 13,500 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Aclaris Therapeutics by 69.7% during the second quarter. The Manufacturers Life Insurance Company now owns 15,831 shares of the biotechnology company’s stock worth $429,000 after buying an additional 6,502 shares during the period. Redmile Group LLC increased its position in shares of Aclaris Therapeutics by 4.3% during the second quarter. Redmile Group LLC now owns 94,560 shares of the biotechnology company’s stock worth $2,564,000 after buying an additional 3,860 shares during the period. Finally, State Street Corp increased its position in shares of Aclaris Therapeutics by 67.1% during the second quarter. State Street Corp now owns 330,755 shares of the biotechnology company’s stock worth $8,971,000 after buying an additional 132,866 shares during the period. Institutional investors own 95.85% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply